Why Are Repeat Echocardiograms Scheduled After Kawasaki Disease and What Do They Track?

The fever broke three days ago. The rash has faded, the peeling fingertips look almost ordinary again, and a four-year-old who would not leave her mother’s lap is now negotiating for a second yogurt. Then the discharge paperwork arrives, and halfway down the page sits a line that makes the whole family go quiet: echocardiogram, two weeks; echocardiogram, six weeks; cardiology clinic to follow.

For most parents this is the first time they hear that kawasaki disease long term follow up is a thing at all. The child looks well. Why keep scanning a heart that, by every outward sign, is fine?

The honest answer is that the part of Kawasaki disease that matters most for the future is invisible from the outside, happens on a predictable timeline, and can be measured to a fraction of a millimeter with a probe pressed gently to a sleeping child’s chest. This article explains what those scans watch, how the schedule is built, and what the results mean.

What does a Kawasaki disease echocardiogram actually look at?

An echocardiogram is an ultrasound of the heart: sound waves bounce off moving tissue and a computer draws the picture in real time. There is no radiation, no needle, and nothing enters the body. For a child it feels like a cool gel and a smooth probe moving over the chest and upper abdomen, usually in a dim room with a screen the child can watch.

After Kawasaki disease the sonographer is looking at the whole heart, but the headline question is narrow. How wide are the coronary arteries? These are the small vessels, a few millimeters across in a preschooler, that wrap around the outside of the heart and feed the muscle itself. The scan measures the inner diameter of the left main coronary artery, the left anterior descending artery, the right coronary artery and, where possible, the circumflex branch, at several points along each one.

Beyond diameter, the team checks the artery walls for brightness or thickening, which can signal inflammation, and looks for any clot inside a widened segment. They assess how strongly the heart squeezes, whether the valves leak, and whether fluid has collected in the sac around the heart. According to the American Heart Association scientific statement on Kawasaki disease, mild valve leakage and reduced pumping function are common during the acute illness and usually settle as inflammation does.

Each measurement is then converted to a Z-score, a number that says how far the artery is from the expected size for a child of that body surface area. The Z-score, not the raw millimeter reading, is what drives nearly every decision that follows, and it is why a measurement that sounds tiny can still matter in a small child.

Why the coronary arteries, and why the timing is so specific

Kawasaki disease is a vasculitis, meaning inflammation of blood vessel walls, and for reasons still not fully understood it has a particular appetite for the coronary arteries. The Mayo Clinic describes it as the leading cause of acquired heart disease in children in developed countries, a striking statement for an illness that, at the bedside, looks like a stubborn fever with red eyes and a rash.

The inflammation attacks the artery wall from the inside out. White cells flood the middle layer, enzymes dissolve the elastic fibers that normally hold the vessel’s shape, and the wall weakens. Blood pressure then does the rest: a weakened segment balloons outward into an aneurysm, a localized widening of the artery. Where the whole segment stretches evenly, clinicians use the word dilation; where a pouch or sausage shape forms, they say aneurysm.

This process has a rhythm. The AHA statement reports that coronary dimensions usually reach their maximum within the first six weeks after fever onset, and that aneurysms rarely appear for the first time after that window. A normal scan at six weeks is therefore reassuring in a way that a normal scan on day three is not. Early scans establish a baseline and catch the small minority of children who already have changes at diagnosis; the later scans catch the peak.

Timing also matters for treatment. The same AHA guidance notes that without intravenous immunoglobulin, roughly 25% of children develop coronary artery aneurysms, and that treatment within the first ten days of fever lowers that figure to about 4%. The echo schedule is designed to answer one question as early as the biology allows: did this child fall into the protected majority, or does the heart need watching for longer?

The standard echocardiogram schedule in the first six weeks

Most children leave hospital with three scans on the calendar, and the pattern is remarkably consistent across guidelines. The AHA statement recommends an echocardiogram at the time of diagnosis, a second at 1–2 weeks, and a third at 4–6 weeks after treatment, for every child whose course is uncomplicated.

The first scan happens while the child is still febrile and often still in hospital. Its job is to find the baseline and to flag anyone who already has dilation, which changes how aggressively the team treats. It also documents pumping function and any pericardial fluid, both of which can be affected by acute inflammation.

The second scan, at one to two weeks, sits on the rising edge of the risk curve. Arteries that were normal at diagnosis may begin to widen here. The team is also watching for anything that would prompt a change in antiplatelet strategy or a repeat course of immunoglobulin in children whose fever did not settle. The AHA guidance notes that 10–20% of children have persistent or recurrent fever after a first infusion, and these children are typically scanned more often.

The third scan, at four to six weeks, is the one families remember. It falls at or just after the usual peak of coronary change. A child whose Z-scores have remained below 2 at this point is, by guideline definition, considered to have no coronary involvement, and the AHA statement allows the team to stop antiplatelet treatment at this stage and to space future visits widely.

Anything abnormal at any of these three points pulls the child onto a different, more frequent pathway, which is where kawasaki disease long term follow up properly begins.

What is a Z-score, and why does it matter more than millimeters?

A two-year-old and a twelve-year-old do not have the same size coronary arteries any more than they wear the same shoes. A reading of three millimeters might be normal in one and alarming in the other. Z-scores solve this by comparing each measurement with a reference range built from healthy children of similar body surface area, a value calculated from height and weight.

The Z-score is simply the number of standard deviations above or below the expected mean. A Z-score of 0 is dead average. A Z-score of 2 means the artery is wider than roughly 97 of 100 healthy children of that size; a Z-score of 5 is far outside anything seen in health. Because the number already accounts for growth, it can be compared from one visit to the next even as the child gets taller.

The AHA statement uses Z-scores to define categories that drive follow-up. Below 2 is no involvement. From 2 to under 2.5 is dilation only. From 2.5 to under 5 is a small aneurysm. From 5 to under 10, with an absolute diameter under 8 mm, is a medium aneurysm. A Z-score of 10 or more, or any diameter of 8 mm or greater, is a large or giant aneurysm.

Two practical points follow. First, the cardiologist will classify the child by the worst artery measurement ever recorded, not the current one, because an artery that has shrunk back to normal size may still have a scarred, less elastic wall. Second, small shifts between scans are expected; a change from Z 1.8 to Z 2.1 reflects measurement variation as much as biology, which is why teams look at trends across several visits rather than reacting to a single number.

Kawasaki disease long term follow up: what each risk level usually involves

Once the six-week scan is done, the follow-up plan is matched to the child’s highest-ever Z-score. The table below summarizes the structure described in the AHA scientific statement. Real schedules are individualized by the treating team, and local practice varies.

Coronary finding (highest ever Z-score)	Typical surveillance described in AHA guidance	What the team is tracking
No involvement (Z below 2)	Assessment at 4–6 weeks; a further review around 12 months is optional, after which discharge from cardiology is reasonable	Confirming the arteries stayed normal through the peak window
Dilation only (Z 2 to under 2.5) that returns to normal	Reassessment at 4–6 weeks and again at 12 months; discharge if normal	Resolution of mild widening
Small aneurysm (Z 2.5 to under 5)	Echo at 6 and 12 months, then yearly if the artery normalizes, with less frequent visits over time	Regression of the aneurysm, wall appearance, any clot
Medium aneurysm (Z 5 to under 10, under 8 mm)	Echo at 3, 6 and 12 months, then yearly; periodic stress testing and cross-sectional imaging in older children	Regression, narrowing at the aneurysm edges, blood flow to heart muscle
Large or giant aneurysm (Z 10 or more, or 8 mm or more)	Echo at 1, 2, 3, 6, 9 and 12 months in year one, then every 3–6 months; stress imaging and CT or MR angiography at intervals; lifelong cardiology care	Clot formation, stenosis, heart muscle perfusion, long-term wall changes

Two things stand out. Follow-up intensity rises steeply with aneurysm size, and the lowest-risk group, which is the large majority of treated children, is genuinely allowed to stop. The purpose of the schedule is not to keep every child in clinic indefinitely; it is to concentrate attention where the risk actually sits.

Who is usually discharged from follow-up, and who is asked to stay

The question families most want answered is whether their child will be in this for life. For most, the answer is no. The AHA statement describes children with no coronary involvement, or with dilation that returns to normal within the first weeks, as a group for whom discharge from cardiology after the 4–6 week assessment, or after an optional review at 12 months, is reasonable. Their long-term heart risk is not considered higher than that of any other child, and the usual advice is simply to follow the heart-healthy habits recommended for everyone.

Children with aneurysms stay. How long depends on size and on what happens next. Small aneurysms often shrink back to a normal diameter over 1–2 years, and once that happens the AHA guidance allows visits to become less frequent, though many centers continue periodic review because the healed wall can remain stiffer than normal. Medium aneurysms are followed yearly at a minimum. Giant aneurysms place a child under cardiology care indefinitely, because the walls of these very wide segments rarely return to normal and the risk of clot or narrowing persists into adulthood.

A few other situations prompt longer or closer follow-up regardless of the six-week result. Children whose fever persisted after the first immunoglobulin infusion, infants under six months, and children whose initial scans showed reduced pumping function or valve leakage may be kept under review for longer. So may children whose early scans were technically difficult, for example because an uncooperative toddler made measurement uncertain.

None of this is decided by a parent reading a table. The treating cardiologist weighs the measurements, the trend, the child’s age and the quality of the images, then sets a plan that can change at any visit.

What the first weeks after Kawasaki disease usually look like

Recovery has a familiar shape, even though every child moves through it at a different pace. In the first week after treatment the fever usually resolves within a day or two of the immunoglobulin infusion. The red eyes fade, the cracked lips heal, and the rash disappears. Appetite and mood return more slowly; irritability is a recognized feature of the acute illness and can linger.

Around the second and third weeks a new sign often appears that alarms parents who were not warned about it: the skin on the fingertips and toes begins to peel in sheets. This is a normal, painless part of the healing phase described by MedlinePlus and the NHS, not a relapse. Some children also develop fine horizontal grooves across the nails a month or two later, which grow out on their own.

Tiredness is common for several weeks. Children may need extra sleep and shorter days at nursery or school, and joint aches can come and go. Most families notice their child is back to baseline energy somewhere between four and eight weeks, though no guideline promises a fixed date.

Through this period the child is usually taking a low-strength antiplatelet medicine, and the team will give specific advice on avoiding contact sports or activities with a high risk of knocks while on it, and on what to do if the child catches influenza or chickenpox. Blood tests to check platelets and inflammation markers may be repeated once or twice.

The 4–6 week echocardiogram typically closes this phase. If the arteries are normal, the AHA statement supports stopping antiplatelet treatment at that visit, with the final decision resting with the prescribing clinician.

What are the long-term effects of Kawasaki disease?

The long-term effects of Kawasaki disease depend almost entirely on what happened to the coronary arteries in the first six weeks. For children whose arteries stayed normal, current evidence summarized by the AHA does not show a measurable increase in later heart disease, and no restrictions on activity, sport or career are advised. This is the outcome for the large majority of treated children.

For children who developed aneurysms, the picture is more nuanced and the artery size is the strongest predictor. Small aneurysms frequently regress to normal lumen diameter. The AHA statement notes, however, that regression happens through thickening of the inner wall rather than true repair of the elastic layer, so the segment can remain less flexible and may not dilate normally with exercise.

Medium and giant aneurysms carry the real risk. Blood moving through a wide, slow-flowing segment can clot, and the junctions where the aneurysm meets normal artery can gradually narrow over years. Both processes can reduce blood supply to the heart muscle, which is why older children in these groups undergo periodic stress testing and, in some cases, CT or MR angiography. The AHA guidance describes giant aneurysms as the group in which myocardial infarction and the need for procedures to restore blood flow are concentrated, and it recommends lifelong cardiology care for them.

Research also continues into whether Kawasaki disease leaves subtler marks: slightly stiffer arteries elsewhere in the body, or altered cholesterol handling. The evidence here is mixed and the clinical significance uncertain. What is well established is that standard cardiovascular risk factors such as smoking, high blood pressure and inactivity matter at least as much for these patients as for anyone else, so the advice to grow up with heart-healthy habits is not generic filler; it is the main modifiable part of the long-term outlook.

Is Kawasaki disease treatable, and how does treatment shape the follow-up?

Yes. Kawasaki disease is very treatable, and the follow-up schedule is in part a measure of how well the treatment worked for a particular child. The mainstay is intravenous immunoglobulin, a purified preparation of antibodies pooled from many donors, given as a single infusion over several hours. Its exact mechanism in Kawasaki disease is not fully understood; the leading explanation is that it dampens the overactive immune response and reduces inflammation in the vessel walls. The AHA statement reports that giving it within the first ten days of fever is associated with a fall in coronary aneurysm rates from roughly 25% to about 4%.

The second component is aspirin, used in the acute phase for its anti-inflammatory effect and afterward for its antiplatelet effect, which makes blood less likely to form clots inside an inflamed or widened artery. How long it continues is set by the echocardiogram findings and decided by the prescribing clinician.

A minority of children, 10–20% according to the AHA guidance, remain febrile or spike again after the first infusion. They are usually offered a second infusion, and some centers add a corticosteroid or another anti-inflammatory agent. Children in this group are at higher risk of coronary changes and are scanned more often.

Treatment also changes one aspect of routine childhood care. Because immunoglobulin contains antibodies that can neutralize live vaccines, the AHA statement advises deferring live vaccines such as measles-mumps-rubella and varicella for 11 months after the infusion. Inactivated vaccines, including influenza, are not affected and are generally encouraged. The child’s pediatrician will adjust the immunization schedule accordingly.

Treatment does not change the need for the 4–6 week scan. Even a textbook response is confirmed, not assumed, by measurement.

Coronary artery aneurysm after Kawasaki disease: what the medicines do, by class

When follow-up scans show an aneurysm, medicines are chosen to lower the risk of clot forming inside it. The specific drug, the duration and any changes are entirely the treating team’s decisions; what follows describes mechanism and typical timelines only.

Antiplatelet medicines, of which aspirin is the most familiar example, make platelets less sticky so they are less likely to clump on the irregular inner wall of a widened artery. The AHA statement describes continuing antiplatelet treatment until a small aneurysm has returned to normal size, and indefinitely for medium and larger aneurysms. In some children a second antiplatelet agent from a different class is added.

Anticoagulants, which work on the clotting cascade rather than on platelets, are generally reserved for giant aneurysms, where blood flows so slowly through the widened segment that a clot can form despite antiplatelet treatment. Options described in guidelines include a vitamin K antagonist, which requires regular blood tests to keep the effect in range, and low-molecular-weight heparin given by injection. Both carry a bleeding risk, so families are counseled about bruising, nosebleeds and what to do after a head injury.

Statins, which lower cholesterol and may also improve the function of the artery lining, have been used in some older patients with persisting aneurysms. The AHA statement notes that evidence for this use in Kawasaki disease is limited and classes it as a reasonable option rather than a standard, so it is not something to request on the strength of this article.

Each echocardiogram feeds back into these choices. A small aneurysm that normalizes may allow medicines to stop; a new clot, or a segment that is narrowing, may prompt escalation or referral for further imaging. The scans and the prescriptions are two halves of the same plan.

What happens at a follow-up echo visit, and how to prepare a child

A follow-up echocardiogram is low-key compared with the hospital stay, but a small child does not know that. A little preparation makes the pictures better and the visit calmer.

The appointment usually lasts 30–60 minutes. The child lies on a couch, often on their side, with the chest bare. Three sticky electrodes record the heart rhythm while the sonographer moves a probe over the chest, the top of the abdomen and the base of the neck. Measuring coronary arteries requires stillness for stretches of several seconds at a time, so for toddlers the team may suggest timing the visit around a nap, bringing a tablet with a favorite program, or feeding a baby during the scan.

Sedation is sometimes used for very young or anxious children when earlier scans could not capture clear images. If so, the team will give fasting instructions and explain the recovery period. Parents can usually stay in the room throughout.

Honest, brief explanations help: it is a special camera that takes pictures of the heart using jelly, it does not hurt, and the jelly washes off. Children who have had many scans often want to see the screen and hear the swooshing sound of blood flow turned up.

After the scan a cardiologist reviews the images, reports the Z-scores and compares them with earlier studies. Many clinics give results the same day; others follow up by letter or at a clinic appointment. It is reasonable to ask for the actual Z-scores and to keep a written record, because a family that moves or changes doctors will need that history. Asking what the plan would be if the numbers changed is also worthwhile: it turns a scan into a conversation rather than a verdict.

Kawasaki disease long term follow up in teenagers and adults

Kawasaki disease is overwhelmingly a childhood illness; the Mayo Clinic and the NHS both note that most cases occur in children under five. Adults almost never develop it. Yet adults with Kawasaki disease are increasingly common for a different reason: children who had aneurysms in the 1980s and 1990s have grown up, and their arteries came with them.

The teenage years are the point at which follow-up most often falls apart. Appointments made by a parent are missed by a sixteen-year-old; a move to college breaks the chain; a young adult feels entirely well and sees no point in a scan. The AHA statement singles out structured transition from pediatric to adult cardiology as a priority for anyone with persisting or previously giant aneurysms, precisely because the risks of clot and narrowing do not fade when the pediatric clinic discharges them.

For adults in this group, surveillance shifts toward tests that suit larger bodies. Echocardiography becomes less able to see the coronary arteries clearly as the chest wall thickens, so CT or MR angiography and stress imaging take on a bigger role. Antiplatelet or anticoagulant treatment continues, and cardiovascular risk factors are monitored closely.

Adults who had Kawasaki disease without coronary involvement are a different story. Current AHA guidance does not recommend ongoing specialist follow-up for them, though it is sensible for them to know their history and mention it to any clinician who asks about heart disease.

Pregnancy deserves a specific mention. Women with persisting aneurysms can and do have healthy pregnancies, but the increased blood volume and clotting tendency of pregnancy call for planning with both cardiology and obstetric teams before conception, including review of which medicines are appropriate. Every detail of that plan belongs with those teams, not with a magazine article.

What people often get wrong about follow-up after Kawasaki disease

“The child looks fine, so the heart must be fine.” Coronary aneurysms cause no symptoms in a child. The only way to know they are absent is to measure, and the peak of change comes weeks after the fever ends, when the child looks healthiest.

“A normal first scan means we can skip the rest.” The scan at diagnosis is a baseline. The AHA statement is explicit that dimensions usually peak within six weeks, so the later scans are the ones that actually answer the question.

“An aneurysm means heart surgery.” Most aneurysms are small, and many regress over 1–2 years. Procedures to restore blood flow are concentrated in the giant aneurysm group, which is a small minority of treated children.

“Once an aneurysm shrinks, it is as if it never happened.” Regression restores the diameter but not the elastic layer. That is why cardiologists classify by the highest-ever Z-score and why some teams keep reviewing a normalized artery.

“Follow-up means restrictions.” Children with no coronary involvement have no activity limits. Even children on antiplatelet medicine are usually encouraged to be active, with specific advice only about high-contact sports.

“Kawasaki disease can be diagnosed with a test.” There is no single blood test. Diagnosis rests on the clinical pattern, with blood tests and the echocardiogram as supporting evidence. This also means it can be missed in infants with incomplete features, a group the AHA guidance treats with particular caution.

“The vaccines just need a short delay.” Live vaccines are deferred for 11 months after immunoglobulin because donor antibodies can block the response; inactivated vaccines continue as normal.

“If it comes back, it will look the same.” Recurrence is uncommon but recognized. Any new prolonged fever in a child with a history of Kawasaki disease deserves prompt review, even if it looks different.

Questions to ask your care team about follow-up echocardiograms

Clinic visits are short and the vocabulary is unfamiliar. Writing questions down beforehand changes the quality of the conversation. These are the ones that tend to matter most.

• What were my child’s Z-scores for each coronary artery at this scan, and how do they compare with the earlier ones?
• Which risk category does that place my child in, and is that based on the highest measurement ever recorded?
• When is the next echocardiogram, and what finding at that scan would change the plan?
• If the arteries are normal at six weeks, will my child be discharged, or do you prefer a review at 12 months?
• How long will the antiplatelet medicine continue, and what should we do if my child is exposed to influenza or chickenpox while taking it?
• Which vaccines need to be rescheduled, and who will coordinate that with our pediatrician?
• Are there any activity or sports restrictions right now, and when would they be lifted?
• If the images were difficult to obtain, would a sedated scan or a different type of imaging give clearer answers?
• What symptoms should prompt us to seek urgent care, and who do we call out of hours?
• Could we have a written summary of the diagnosis, treatment dates and all echo results to keep at home?

For families of children with medium or giant aneurysms, a second set of questions becomes relevant over time: when stress testing or CT or MR angiography will be considered, what the plan is for transition to adult cardiology, and whether a referral to a center with specific experience in long-term Kawasaki disease care would be helpful. The answers will differ from child to child, and they should. A plan that fits the measurements in front of the cardiologist is worth more than any general schedule.

When to call your doctor

Most of the follow-up period is uneventful, and the scheduled scans do the watching. A few situations should not wait for the next appointment.

Seek emergency care immediately if a child who has had Kawasaki disease develops chest pain or pressure, pain spreading to the arm, jaw or back, sudden breathlessness at rest, fainting or near-fainting, a very pale, sweaty or gray appearance, or in a baby or toddler, inconsolable crying with pallor, vomiting and extreme lethargy that comes on abruptly. In a child with known aneurysms these can be signs of reduced blood flow to the heart muscle and are treated as emergencies.

Call the care team the same day if fever returns within the first few weeks after treatment, if the child develops a new rash, red eyes or swollen hands and feet, if there is unusual bruising, nosebleeds that will not stop, blood in the urine or stool, or any head injury while on antiplatelet or anticoagulant medicine, or if the child has been exposed to chickenpox or influenza while taking aspirin.

Contact the team before the next visit if a scheduled echocardiogram has been missed or cannot be arranged, if a new clinician proposes starting, stopping or changing any medicine without knowledge of the Kawasaki history, or if the family is moving and needs records transferred. For adults with a history of aneurysms, any new chest discomfort on exertion, unexplained breathlessness or palpitations warrants prompt review.

None of these lists is exhaustive. When something about a child seems wrong, trusting that instinct and making the call is always the right choice; the team would far rather hear about a false alarm than miss something real.

Frequently asked questions

What are the long-term effects of Kawasaki disease?

They depend on whether the coronary arteries were affected in the first six weeks. Children whose arteries stayed normal are not considered to carry extra heart risk and need no restrictions. Small aneurysms often regress over 1–2 years, though the wall may remain less elastic. Medium and giant aneurysms carry a lasting risk of clot and narrowing, which is why those children stay under cardiology care, in the largest cases for life.

Is Kawasaki disease treatable?

Yes. Intravenous immunoglobulin given within the first ten days of fever markedly reduces the chance of coronary aneurysms, and most treated children recover fully. Aspirin is used for its anti-inflammatory and later antiplatelet effects. A minority need a second infusion or additional anti-inflammatory treatment if fever persists. Even with a textbook response, the 4–6 week echocardiogram is still needed to confirm the arteries stayed normal.

What is the rash associated with Kawasaki disease?

It is typically a widespread, red, blotchy or measles-like rash that appears within the first days of fever, often prominent on the trunk and in the diaper area, without blisters or crusting. It fades as the fever settles. A separate, later change is peeling skin on the fingertips and toes around the second or third week, which is part of recovery rather than a sign of relapse.

Can adults get Kawasaki disease?

Rarely. Most cases occur in children under five and new diagnoses in adults are unusual. Adults with Kawasaki disease are more often people who had it as children and still have coronary aneurysms. For them, follow-up shifts toward CT or MR angiography and stress imaging, since echocardiography sees adult coronary arteries less clearly, and planned transition from pediatric to adult cardiology is strongly encouraged.

How many echocardiograms does a child need after Kawasaki disease?

The AHA statement recommends three for an uncomplicated course: at diagnosis, at 1–2 weeks and at 4–6 weeks. If all are normal, an optional review around 12 months may follow before discharge. Children with aneurysms need more, scheduled according to size; a giant aneurysm may mean six scans in the first year and then every 3–6 months indefinitely.

What does a coronary artery aneurysm from Kawasaki disease mean for my child?

It means a segment of a heart artery widened because inflammation weakened its wall. Small aneurysms frequently shrink back to normal diameter and need only periodic scans and antiplatelet medicine for a time. Medium and giant aneurysms require closer surveillance and longer treatment because blood can clot in the widened segment or the artery can narrow at its edges over years. The cardiologist sets the plan from the measurements.

Why is a Kawasaki disease echocardiogram repeated if the first one was normal?

Because the first scan is a baseline, not a verdict. Coronary dimensions usually reach their maximum within six weeks of fever onset, and aneurysms that were not present at diagnosis can appear in that window. The 1–2 week and 4–6 week scans are timed to catch the rise and the peak. A normal six-week scan is what allows the team to call the arteries unaffected.

Can my child play sports during Kawasaki disease follow-up?

Usually yes. Children with no coronary involvement have no activity limits once recovered. Children taking antiplatelet or anticoagulant medicines are generally encouraged to stay active but are advised to avoid high-contact or collision sports because of bleeding risk. Children with medium or giant aneurysms receive individualized advice, sometimes guided by stress testing. The treating cardiologist makes these calls.

Does Kawasaki disease come back?

Recurrence is uncommon but recognized, and it does not always look the same as the first episode. Any new prolonged fever in a child with a history of Kawasaki disease should be reviewed promptly, with the earlier diagnosis mentioned to the clinician. A recurrence is treated and followed with the same echocardiogram schedule as a first episode, since the coronary arteries are at risk again.

Why are vaccines delayed after Kawasaki disease treatment?

Intravenous immunoglobulin contains antibodies from many donors, and those antibodies can neutralize live vaccines before the child’s immune system responds. The AHA statement therefore advises deferring live vaccines such as measles-mumps-rubella and varicella for 11 months after the infusion. Inactivated vaccines, including influenza, are unaffected and are generally encouraged, particularly for children taking aspirin.

References

• NHS: Kawasaki disease
• MedlinePlus Medical Encyclopedia: Kawasaki disease

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.